Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02655393
Other study ID # 15.02.AMZ
Secondary ID OP095615.AMA - O
Status Completed
Phase Phase 1
First received
Last updated
Start date January 2016
Est. completion date December 2016

Study information

Verified date August 2022
Source Amazentis SA
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Part A: The study is a double-blind, randomized, single ascending doses, study in 24 healthy elderly male and female volunteers. Each subject will be randomized for two subsequent doses in three cohorts. Part B: The study is a double-blind, randomized, multiple ascending doses study in 36 healthy elderly male and female volunteers. Subjects will be randomized to receive study product or placebo for 28 days.


Description:

Part A: Single Ascending Dose study of AMAZ-02 with 3 cohorts (each cohort n=8 subjects, total n=24 subjects). Cohorts undergo two periods of single dose intervention separated by 3 week washout. Adverse events, clinical biochemistry for safety assessment and plasma and urine collected for pharmacokinetic measurement for parent and metabolite levels in circulation. Part B: Multiple Ascending Dose study with 3 cohorts (each cohort n=12 subjects, total n=36 subjects). 28 day administration with AMAZ-02 for safety, PK and PD assessment.


Recruitment information / eligibility

Status Completed
Enrollment 60
Est. completion date December 2016
Est. primary completion date September 2016
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 61 Years to 85 Years
Eligibility Inclusion Criteria: 1. Healthy male and female elderly subject, aged between 61 and 85 years inclusive; 2. Non-smoker subject or smoker of not more than 5 cigarettes a day; 3. Body Mass Index (BMI) between 18 and 32 kg/m2 inclusive; 4. Certified as healthy by a comprehensive clinical assessment (detailed medical history and complete physical examination); 5. Normal Blood Pressure (BP) and Heart Rate (HR) at the screening visit after 10 minutes in supine position: - 95 mmHg = Systolic Blood Pressure (SBP) = 160 mmHg, - 50 mmHg = Diastolic Blood Pressure (DBP) = 95 mmHg, - 50 bpm < HR < 80 bpm, - Or considered NCs by investigators; 6. Normal ECG recording on a 12-lead ECG at the screening visit: - 120 < PR < 220 ms, - QRS < 120 ms, - QTcf < 430 ms for male and < 450 ms for female, - No sign of any trouble of sinusal automatism, - Or considered NCS by investigators; 7. Laboratory parameters within the normal range of the laboratory (haematological, blood chemistry tests, urinalysis). Individual values out of the normal range can be accepted if judged clinically non relevant by the Investigator; 8. Normal dietary habits; 9. Demonstrate sedentary behaviour defined as having an activity category of 1 as assessed by the International Physical Activity Questionnaire (IPAQ). Activity level is < 600 MET (metabolic equivalent unit - minutes per week and limited to light intensity activities. 10. Accept to refrain consuming certain foods and supplements at least two weeks before inclusion. 11. Comprehension of the nature and purpose of the study and ability to communicate in person and by telephone in a manner that allows all protocol procedures to be carried out safety and reliably in the opinion of the investigative site staff 12. Ability to take up to 8 capsules of study medication 13. Signing a written informed consent prior to selection; 14. Covered by Health Insurance System and / or in compliance with the recommendations of National Law in force relating to biomedical research. Exclusion Criteria: 1. Any history or presence of cardiovascular, pulmonary, gastro-intestinal, hepatic, renal, metabolic, hematological, neurologic, psychiatric, systemic or infectious disease; 2. Frequent headaches and / or migraine, recurrent nausea and / or vomiting; 3. Symptomatic hypotension whatever the decrease of blood pressure or asymptomatic postural hypotension defined by a decrease in SBP or DBP equal to or greater than 20 mmHg within two minutes when changing from the supine to the standing position; 4. Blood donation (including in the frame of a clinical trial) within 2 months before administration; 5. General anaesthesia within 3 months before administration; 6. Presence or history of drug hypersensitivity, or allergic disease diagnosed and treated by a physician; 7. Lactose intolerance, milk protein or soy allergy. 8. Inability to abstain from intensive muscular effort; 9. No possibility of contact in case of emergency; 10. Use of any of the prohibited medications as detailed in the concomitant medication section 11. History or presence of drug or alcohol abuse (alcohol consumption > 40 grams / day); 12. Excessive consumption of beverages with xanthine bases (> 4 cups or glasses / day); 13. Positive Hepatitis B surface (HBs) antigen or anti Hepatitis C Virus (HCV) antibody, or positive results for Human Immunodeficiency Virus (HIV) 1 or 2 tests; 14. Positive results of screening for drugs of abuse; 15. Subject who, in the judgment of the Investigator, is likely to be non-compliant or uncooperative during the study, or unable to cooperate because of a language problem, poor mental development; 16. Exclusion period of a previous study; 17. Administrative or legal supervision; 18. Subjects should not have participated in previous clinical trials in the last 3 months and received compensation beyond a certain approved and predefined limit

Study Design


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
Mitopure


Locations

Country Name City State
France Eurofins Optimed Gières

Sponsors (2)

Lead Sponsor Collaborator
Amazentis SA Eurofins Optimed

Country where clinical trial is conducted

France, 

References & Publications (1)

Andreux PA, Blanco-Bose W, Ryu D, Burdet F, Ibberson M, Aebischer P, Auwerx J, Singh A, Rinsch C. The mitophagy activator urolithin A is safe and induces a molecular signature of improved mitochondrial and cellular health in humans. Nat Metab. 2019 Jun;1(6):595-603. doi: 10.1038/s42255-019-0073-4. Epub 2019 Jun 14. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Number of subjects with adverse events 6 weeks
Secondary Plasma concentrations of AMAZ-02 and its metabolites over time and maximal plasma concentration (Cmax) 6 weeks
Secondary Exposure to AMAZ-02 measured as area under the curve (AUC) 6 weeks
Secondary Half-live (t 1/2) of AMAZ-02 and its metabolites 6 weeks
Secondary Cmax of AMAZ-02 and its metabolites in urine 6 weeks
Secondary AUC of AMAZ-02 and its metabolites in urine 6 weeks
Secondary Gene expression for mitochondrial biomarkers in PBMC 6 weeks
Secondary Gene expression for mitochondrial biomarkers in muscle tissue 6 weeks
Secondary Blood Lipid Profile 6 weeks
See also
  Status Clinical Trial Phase
Completed NCT05433233 - Effects of Lifestyle Walking on Blood Pressure in Older Adults With Hypertension N/A
Recruiting NCT06032065 - Sequential Multiple Assessment Randomized Trial of Exercise for PAD: SMART Exercise for PAD (SMART PAD) Phase 3
Completed NCT05293730 - Trial of the Impact of the Electronic Frailty Integrated With Social Needs N/A
Recruiting NCT03932162 - Gene Expression Changes In Young and Geriatric Skin Early Phase 1
Completed NCT04064528 - Effects of Age on Amino Acid Delivery to Tendon N/A
Completed NCT03366129 - Blood-Brain Barrier Disruption in People With White Matter Hyperintensities Who Have Had a Stroke
Completed NCT06029920 - Influence of Overground Walking on Biomarkers, Cognitive Function, and Quality of Life in Elderly With Mild Cognitive Impairment N/A
Recruiting NCT05543980 - Leg Heat Therapy in Elderly Individuals Phase 2
Recruiting NCT05566938 - Study to Design a Precision Nutrition Strategy at a Group Level in the Elderly N/A
Completed NCT04894929 - Comprehensive Geriatric Assessment in the Monitoring of Functional Improvement N/A
Not yet recruiting NCT06071130 - Emotion, Aging, and Decision Making N/A
Enrolling by invitation NCT04641663 - Multi-target Dietary Supplement Tolerability in an Aging Population (MTDSST) N/A
Completed NCT04088006 - The Evaluation of Efficacy and Safety of Hyaluronic Acid Injection on Skin Moisturization and Elasticity N/A
Completed NCT03695081 - Patient Pathway Pharmacist - Optimal Drug-related Care N/A
Recruiting NCT05424263 - Acetate and Age-associated Arterial Dysfunction Phase 2
Completed NCT05601713 - Mitigating Heat-induced Physiological Strain and Discomfort in Older Adults Via Lower Limb Immersion and Neck Cooling N/A
Completed NCT04551339 - Zinc Versus Multivitamin Micronutrient Supplementation in the Setting of COVID-19 N/A
Recruiting NCT04997577 - Speech Perception and High Cognitive Demand N/A
Completed NCT05922475 - Efficacy of Pre-sleep or Post-exercise Protein During 12 Weeks of Resistance Exercise Training N/A
Completed NCT04015479 - Peanut Protein Supplementation to Augment Muscle Growth and Improve Markers of Muscle Quality and Health in Older Adults N/A